| [1] Huntly BJ, Francois G, Reid AG, et al. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions[J]. Blood, 2003, 102(6):2205-2212.[2] Huntly BJ, Reid AG, Bench AJ, et al. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia[J]. Blood, 2001, 98(6):1732-1738.[3] 应逸, 毛平, 杜庆华, 等. 荧光原位杂交检测慢性粒细胞白血病衍生9号染色体缺失的研究[J]. 临床血液学杂志, 2010, 23(1):9-11.[4] Yoong Y, Vandewalker TJ, Carlson RO, et al. Clinical correlates of submicroscopic deletions involving the ABL-BCR translocation region in chronic myeloid leukemia[J]. Eur J Haematol, 2005, 74(2):124-127.[5] Pienkowska-Grela B, Woroniecka R, Solarska I, et al. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript[J]. Cancer Genet Cytogenet, 2007, 174(2):111-115.[6] Sinclair PB, Nacheva EP, Leversha M, et al. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia[J]. Blood, 2000, 95(3):738-743.[7] Kolomietz E, Al-Maghrabi J, Brennan S, et al. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis[J]. Blood, 2001, 97(11):3581-3588.[8] Cohen N, Rozenfeld-Granot G, Hardan I, et al. Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene:expression profiling, resistance to interferon therapy, and poor prognosis[J]. Cancer Genet Cytogenet, 2001,128(2):114-119.[9] Gorusu M, Benn P, Li Z, et al. On the genesis and prognosis of variant translocations in chronic myeloid leukemia[J]. Cancer Genet Cytogenet, 2007,173(2):97-106.[10] Bacher U, Schnittger S, Kern W, et al. The incidence of submicroscopic deletions in reciprocal translocations is similar in acute myeloid leukemia, BCR-ABL positive acute lymphoblastic leukemia, and chronic myeloid leukemia[J]. Haematologica, 2005, 90(4):558-559.[11] Specchia G, Albano F, Anelli L, et al. Derivative chromosome 9 deletions in chronic myeloid leukemia are associated with loss of tumor suppressor genes[J]. Leuk Lymphoma, 2004,45(4):689-694.[12] Richebourg S, Eclache V, Perot C, et al. Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy[J].Cancer Genet Cytogenet, 2008, 182(2):95-102.[13] 周璇, 刘晓力, 曹睿, 等. 精氨代琥珀酸合成基因缺失在慢性髓性白血病中的预后意义[C]. 中华医学会第十二次全国血液学学术会议论文集, 2012:122-123.[14] Quintaás-CardamaA, KantarjianH, ShanJQ, et al. Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib[J].Cancer,2011,117(22):5085-5093.[15] Castagnetti F, Testoni N, Luatti S, et al. Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate:GIMEMA CML Working Party analysis[J]. J Clin Oncol,2010,28(16):2748-2754.[16] Bennour A,Ouahchi I, Youssef YB,et al.Molecular cytogenetic study of derivative chromosome 9 deletion in chronic myeloid leukemia patients[J].Med Oncol, 2012,29(2):1151-1160. |
